New approaches to prediction of immune responses to therapeutic proteins during preclinical development

Drugs in R and D

Volumn 9, Issue 6, 2008, Pages 385-396

  Perry, Laura C A ^a   Jones, Timothy D ^a   Baker, Matthew P ^a  

^a Antitope Ltd   (United Kingdom)

Author keywords

Immunogenetic stimulants, therapeutic use; Proteins, therapeutic use

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; EPITOPE; ERYTHROPOIETIN; HIRUDIN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NEUTRALIZING ANTIBODY; T LYMPHOCYTE RECEPTOR;

ANTIBODY RESPONSE; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; COMPUTER MODEL; DRUG DEVELOPMENT; EX VIVO STUDY; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IN VIVO STUDY; NONHUMAN; PREDICTION; PRIMATE; PRIORITY JOURNAL; REVIEW;

ANIMALS; DRUG EVALUATION, PRECLINICAL; EPITOPES, T-LYMPHOCYTE; FORECASTING; HUMANS; MICE; MODELS, BIOLOGICAL; PRIMATES; PROTEINS;

EID: 55849146298     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/0126839-200809060-00004     Document Type: Review

References (50)

1. Wadhwa M, Skog AL, Bird C, et al. Immunogenicity of granulocyte- macrophage colony-stimulating factor (GM-CSF) products in patients undergoing combination therapy with GM-CSF. Clin Cancer Res 1999; 5 (6): 1353-61
2. Bertolotto A, Malucchi S, Milano E, et al. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations. Immunopharmacology 2000; 48 (2): 95-100
3. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003; 18 Suppl. 8: viii37-41
4. Stravitz RT, Chung H, Sterling RK, et al. Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C. Am J Gastroenterol 2005; 100 (6): 1415-9
5. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98 (12): 3241-8
6. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100 (10): 3457-69
7. Shankar G, Shores E, Wagner C, et al. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol 2006; 24 (6): 274-80
8. Bachmann M, Zinkernagel R. Neutralizing antiviral B-cell responses. Annu Rev Immunol 1997; 15: 235-70
9. Kivisäkk P, Alm GV, Tian WZ, et al. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis. Mult Scler 1997; 3 (3): 184-90
10. Stickler M, Valdes AM, Gebel W, et al. The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4(+) T-cell epitope human interferon-beta. Genes Immun 2004; 5 (1): 1-7
11. Yeung VP, Chang J, Miller J, et al. Elimination of an immunodominant CD4+ T cell epitope in human IFN-beta does not result in an in vivo response directed at the subdominant epitope. J Immunol 2004; 172 (11): 6658-65
12. Barbosa MD, Vielmetter J, Chu S, et al. Clinical link between MHC class II haplotype and interferon-beta (IFN-beta) immunogenicity. Clin Immunol 2006; 18 (1): 42-50
13. Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007; 10 (2): 219-27
14. Reche PA, Glutting JP, Reinherz EL. Prediction of MHC class binding peptides using profile motifs. Hum Immunol 2002; 63: 701-9
15. Reche PA, Glutting JP, Zhang H, et al. Enhancement to the RANKPEP resource for the prediction of peptide binding MHC molecules using profiles. Immunogenetics 2004; 56 (6): 405-19
16. Singh H, Raghava GPS. ProPred: prediction of HLA-DR binding sites. Bioinformatics 2001; 17 (12): 1236-7
17. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand database using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999; 17: 555-61
18. Nielsen M, Lundegaard C, Lund O. Prediction of MHC class binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics 2007 8: 238-50
19. Jones TD, Hanlon M, Smith BJ, et al. The development of modified human IFN-alpha2b linked to the Fc portion human IgG1 as a novel potential therapeutic for the treatment of hepatitis C virus infection. J Interferon Cytokine Res 2004; 24 (9): 560-72
20. Jones TD, Phillips WJ, Smith BJ, et al. Identification and removal of a promiscuous CD4+ T cell epitope from the C1 domain of factor VIII. J Thromb Haemost 2005; 3 (5): 991-1000
21. Jaber A, Baker M. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J Pharm Biomed Anal 2007; 43 (4): 1256-61
22. Jaber A, Driebergen R, Giovannoni G, et al. The Rebif new formulation story: it's not trials and error. Drugs R&D 2007; 8 (6): 335-48
23. Tangri S, Mothé BR, Eisenbraun J, et al. Rationally engineered therapeutic proteins with reduced immunogenicity. J Immunol 2005; 174: 3187-96
24. Milowsky MI, Nanus DM, Kostakoglu L, et al. Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol 2007; 25 (5): 540-7
25. Bander NH, Milowsky MI, Nanus DM, et al. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23 (21): 4591-601
26. Macfarlane DJ, Smart RC, Tsui WW, et al. Safety, pharmaco-kinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22- 80B3 Fab'. Eur J Nucl Med Mol Imaging 2006; 33 (6): 648-56
27. Vallabhajosula S, Goldsmith SJ, Kostakoglu L, et al. Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res 2005; 11 (19 Pt 2): 7195s-200s
28. Bander NH, Nanus DM, Milowsky MI, et al. Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol 2003; 30 (5): 667-76
29. Nanus DM, Milowsky MI, Kostakoglu L, et al. Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol 2003; 170 (6 Pt 2): S84-8
30. Baker MP, Jones TD. Identification and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 2007; 10 (2): 219-27
31. Hermeling S, Jiskoot W, Crommelin D, et al. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm Res 2005; 22 (6): 847-51
32. Hermeling S, Aranha L, Damen JM, et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005; 22 (12): 1997-2006
33. Bugelski PJ, Treacy G. Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans. Curr Opin Mol Ther 2004; 6 (1): 10-6
34. European Medicines Agency (EMEA) and Committee for Medicinal Products for Human Use (CHMP). Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins [online]. Available from URL: http://www.emea.europa.eu/pdfs/human/biosimilar/1432706enfin.pdf [Accessed 2008 Jul 24]
35. Kennedy RC, Shearer MH, Hildebrand W. Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine 1997; 15 (8): 903-8
36. Bontrop RE, Otting N, de Groot NG, et al. Major histocompatibility complex class II polymorphisms in primates. Immunol Rev 1999; 167: 339-50
37. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 55 (10): 1018-28
38. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 1995; 38 (11): 1589-94
39. Vanderschueren SM, Stassen JM, Collen D. On the immunogenicity of recombinant staphylokinase in patients and in animal models. Thromb Haemost 1994; Aug; 72 (2): 297-301
40. Stephens S, Emtage S, Vetterlein O, et al. Comprehensive pharmacokinetics of a humanized antibody and analysis of residual anti-idiotypic responses. Immunology 1995; 85 (4): 668-74
41. Green JD, Terrell TG. Utilization of homologous proteins to evaluate the safety of recombinant human proteins - case study: recombinant human interferon-gamma (rhIFN-gamma). Toxicol Lett 1992; 64-65 Spec No: 321-7
42. Prümmer O, Fiehn C, Gallati H. Anti-interferon-gamma antibodies in a patient undergoing interferon-gamma treatment for systemic mastocytosis. J Interferon Cytokine Res 1996; 16 (7): 519-22
43. Truneh A, Frescatore RL, Thiem P, et al. Humoral response of cynomolgus macaques to human soluble CD4: antibody reactivity restricted to xeno-human determinants. Cell Immunol 1990; 131 (1): 98-108
44. Schooley RT, Merigan TC, Gaut P, et al. Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) an AIDS-related complex: a phase I-II escalating dosage trial. Ann Intern Med 1990; 112 (4): 247-53
45. Hermeling S, Aranha L, Damen JM, et al. Structural characterization and immunogenicity in wild-type and immune tolerant mice of degraded recombinant human interferon alpha2b. Pharm Res 2005; 22 (12): 1997-2006
46. Hermeling S, Jiskoot W, Crommelin D, et al. Development of a transgenic mouse model. Pharm Res 2005; 22 (6): 847-51
47. Behrmann M, Pasi J, Saint-Remy JM, et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88 (2): 221-9
48. Reipert BM, Schoppmann A, Schwarz HP. A caution on the use of murine hemophilia models for comparative immunogenicity studies of FVIII products with different protein compositions. Thromb Haemost 2003; 89 (6): 1110-2
49. Reipert BM, Hausl C, Sasgary M, et al. Humanized E17 hemophilic mice are a major breakthrough in the design of new preclinical models for developing factor VIII products with reduced immunogenicity. Oral presentation at the 49th annual meeting of the American Association of Hematology; 2007 Dec; Atlanta (GA); Blood 110: 782
50. Traggiai, E, Chicha L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004; 304: 104-7